These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16835966)

  • 21. Multiple myeloma therapies.
    Strobeck M
    Nat Rev Drug Discov; 2007 Mar; 6(3):181-2. PubMed ID: 17396289
    [No Abstract]   [Full Text] [Related]  

  • 22. New Treatments and Insights in Multiple Myeloma.
    Faiman B; Noonan K
    ONS Connect; 2016 Jun; 31(6):4 p following 31. PubMed ID: 27430103
    [No Abstract]   [Full Text] [Related]  

  • 23. [Multiple melanoma-progress in understanding of molecular mechanism and improvement in treatment outcome with introduction of new drugs for multiple myeloma].
    Hanamura I; Iida S
    Gan To Kagaku Ryoho; 2010 May; 37(5):816-21. PubMed ID: 20524255
    [No Abstract]   [Full Text] [Related]  

  • 24. The use of topoisomerase I inhibitors in multiple myeloma.
    Kraut EH; Ju R; Muller M
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Searching for truth--from biblical to modern times.
    Antman KH
    J Clin Oncol; 1986 Oct; 4(10):1441-2. PubMed ID: 3760918
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapeutic experiences in multiple myeloma].
    Sonntag R; Favre E; Martz G
    Schweiz Med Wochenschr; 1972 Nov; 102(44):1588-9. PubMed ID: 4566555
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical management of myeloma--state of the art.
    Harousseau JL
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
    Dalton WS
    Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
    [No Abstract]   [Full Text] [Related]  

  • 29. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple myeloma with extramedullary disease.
    Oriol A
    Adv Ther; 2011 Nov; 28 Suppl 7():1-6. PubMed ID: 22105527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Trends in development of novel therapeutic agents for multiple myeloma].
    Kuroda J
    Rinsho Ketsueki; 2012 Oct; 53(10):1699-708. PubMed ID: 23037742
    [No Abstract]   [Full Text] [Related]  

  • 32. [Bortezomib in second-line therapy].
    Musch A
    Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891
    [No Abstract]   [Full Text] [Related]  

  • 33. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
    Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
    Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approval summary for bortezomib for injection in the treatment of multiple myeloma.
    Bross PF; Kane R; Farrell AT; Abraham S; Benson K; Brower ME; Bradley S; Gobburu JV; Goheer A; Lee SL; Leighton J; Liang CY; Lostritto RT; McGuinn WD; Morse DE; Rahman A; Rosario LA; Verbois SL; Williams G; Wang YC; Pazdur R
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3954-64. PubMed ID: 15217925
    [No Abstract]   [Full Text] [Related]  

  • 37. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
    Richardson P
    Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.
    Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):839-54. PubMed ID: 22716498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice.
    SanMiguel J; Facon T; Cavo M
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):s4-s10. PubMed ID: 18567204
    [No Abstract]   [Full Text] [Related]  

  • 40. Lenalidomide: second cancers.
    Prescrire Int; 2012 May; 21(127):130. PubMed ID: 22844687
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.